by Electroporation instruments are used in various advanced biological applications like gene delivery and sequencing. These instruments help deliver therapeutic molecules into cells and tissues through an electrical pulse. They allow efficient and controlled delivery of exogenous molecules into cells without significant cytotoxic effects. Electroporation has gained traction as a non-viral gene delivery method for in vivo gene therapies. The need to develop enhanced gene therapies with minimal side effects is boosting the demand for electroporation instruments globally. With recent advancements, these instruments offer precise transfection while preserving cell viability. They facilitate high throughput transfection experiments in a quick and reproducible manner.
The global Electroporation Instruments Market is estimated to be valued at US$ 242.41 Mn in 2023 and is expected to exhibit a CAGR of 4.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the electroporation instruments market is the development of advanced instruments with portability and cell viability optimization features. Companies are focusing on developing equipment with customized protocols to achieve enhanced transfection efficiency while minimizing cytotoxicity. For instance, Bio-Rad Laboratories launched an electroporator specifically for CRISPR genome editing applications. It ensures high transfection rates with minimal cell death. Similarly, BEX Co has developed portable electroporation devices that facilitate easy transfection of cells in research settings outside laboratories. Such innovations are expanding the utilization of electroporation techniques for wider applications. This growing trend toward user-friendly instruments with optimized results is expected to propel the electroporation instruments market during the forecast period.
Porter’s Analysis
Threat of new entrants: Low barriers to entry in terms of skills and technology required. However, established players have strong distribution network and brand recognition.
Bargaining power of buyers: Buyers have moderate bargaining power due to availability of substitute products. However, technological advantages retained by few leading vendors.
Bargaining power of suppliers: Suppliers have low to moderate bargaining power as raw materials used in electroporation instruments manufacturing are commodity chemicals available from numerous suppliers.
Threat of new substitutes: Threat of substitution is moderate as alternative gene delivery methods like microinjection, viral and mechanical methods are used. However, electroporation provides advantages of high transfection efficiency and ease of use.
Competitive rivalry: Industry features many global and regional players. Competition is based on product performance, pricing, innovation and quality.
Key Takeaways
The Global Electroporation Instruments Market Size is expected to witness high growth. The global Electroporation Instruments Market is estimated to be valued at US$ 242.41 Mn in 2023 and is expected to exhibit a CAGR of 4.4% over the forecast period 2023 to 2030.
The market in North America region is expected to dominate during the forecast period owing to developed healthcare infrastructure and focus on research activities in the region. North America accounts for the largest share in the electroporation instruments market due to presence of major instrument companies and higher adoption of advanced technologies for research activities in the region. Asia Pacific is expected to witness fastest growth due to rising R&D expenditure, increasing life science research and growing genomics and cell biology research in countries like China and India.
Key players operating in the electroporation instruments market are Bio-Rad Laboratories, Inc, Thermo Fisher Scientific Inc., BTX ( a division of Harvard Bioscience), Celetrix, LLC., Gamma Biosciences, Merck KgaA, Eppendorf SE, MaxCyte, Inc. BEX CO.,LTD., Lonza, Altogen Biosystems, Ala Scientific Instruments, Inc., BioEra Life Sciences Pvt. Ltd., and Ichor Medical Systems. Thermo Fisher Scientific Inc. and Bio-Rad Laboratories, Inc. together command major share of the market.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
